■ Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company (SPARC) said the FDA has approved Xelpros as the first and only benzalkonium chloride (BAK)-free formulation of latanoprost for IOP reduction in open-angle glaucoma or ocular hypertension. The approval is from Sun Pharma’s Halol facility in Gujarat, India.

Benzalkonium chloride is a preservative commonly used in topical ocular preparations. Xelpros was developed using SPARC’s proprietary Swollen Micelle Microemulsion technology.